CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; and CS-2023 to treat meningitis. The company was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
Research context
CanSino Biologics Inc appears in PyInvesting’s Hong Kong Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
CanSino Biologics Inc is currently in a long term uptrend where the price is trading 32.2% above its 200 day moving average.
From a valuation standpoint, the stock is 2863.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 3335.1.
CanSino Biologics Inc's total revenue rose by 95.2% to $19M since the same quarter in the previous year.
Its net income has dropped by 238.1% to $-294M since the same quarter in the previous year.
Finally, its free cash flow fell by 6.5% to $-306M since the same quarter in the previous year.
Based on the above factors, CanSino Biologics Inc gets an overall score of 2/5.